Sensius is a world leader in personalized thermotherapy focused on delivering better and more balanced treatment outcomes for each individual cancer patient undergoing radiotherapy.
Sensius has created a personalized, deep penetrating thermotherapy solution, using proprietary technology and software, able to optimize the treatment regimen for each cancer patient. Sensius’ thermotherapy solution has been designed to fit seamlessly into the workflow of cancer patients undergoing treatment with radiotherapy.
Sensius’ thermotherapy technology has been validated by a growing body of clinical data and KOL support from a broad range of cancer specialists.
Sensius’ thermotherapy products have a clear path to market in Europe and the US, via a CE Mark filing in Europe and US IDE filing. The initial target indication is head and neck cancer, which is expected to be followed by breast cancer and melanoma.